Mold-Tek Packaging LtdQ4 FY26
Mold-Tek Packaging Ltd Q4 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹702P/E: 32.3Market Cap: ₹2.3K CrSector: Industrial Products
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Overall volume growth for current fiscal year expected close to 8-9%, below earlier guidance of 10-15%. (Page 12)
- →Confident of double-digit volume growth next year driven by pharma, paints, and Qpack segments. (Pages 10-11, 14)
- →Paint segment volume growth anticipated around 10-15%, with ABG volumes projected to grow 40-50%. (Pages 10, 16)
- →Pharma segment targeted to grow from ~INR8 crores this year to INR30-35 crores next year, potentially doubling to INR60-65 crores by FY '27. (Pages 10, 18)
- →Thin wall (high-margin) packs expected to register ~15% volume growth next year. (Page 14)
- →Food and FMCG segment targeting double-digit growth, supported by new plant at Panipat and new products like Horlicks and Surf Excel. (Pages 10-11)
- →EBITDA per kg expected to cross INR38 by Q4 and target INR40 per kg next financial year, driven by high-margin pharma contributions. (Page 7)
Margin guidance
Category 1- →Company expects double-digit volume growth next year, aiming for 10-15%, driven by improved pharma and ABG segment performance.
- →Pharma segment projected to grow significantly, with revenue potentially reaching INR30-40 crores next year and doubling to INR60-65 crores by FY '27.
- →EBITDA per kg expected to cross INR38 in Q4 FY25 and potentially INR40 in FY26 due to increased high-margin pharma sales.
- →Other segments like food, FMCG, and Qpack are also expected to see double-digit growth, offsetting slower growth in paints and lubes.
- →Margins likely to improve as pharma contribution rises, which offers higher realizations (INR300-350/kg vs. current average INR206/kg).
- →Increased capacity utilization and new product commercialization in pharma should enhance profitability and overall earnings.
- →Operating earnings and profits expected to benefit from high-value pharma business and expanding IML adoption in paints.
3 more insights locked — sign up free to unlock
Fundraise plans
- →The company is planning additional investments in the pharma segment for FY '26, estimated between INR 25 crores to INR 40 crores.
- →These investments primarily cover additional machines and molds; land and building are already in place.
- →There may also be further expansion in Sultanpur premises with potential additional capex of INR 8 crores to INR 10 crores, but decisions are not finalized.
- →Other plants (Cheyyar, Panipat, Mahad) will only see balancing equipment investments, with Mahad seeing around INR 10-15 crores capex.
- →Next financial year’s total capex is expected to be around INR 60-65 crores, significantly lower than INR 120 crores+ spent in previous years.
- →There is no explicit mention of any planned new fundraising through debt or equity in the current or upcoming period shared in the transcript.
Order book
- →No specific details on the current or expected order book or pending orders are mentioned explicitly in the transcript.
- →However, growth expectations are linked to key customers like Asian Paints and Aditya Birla Group (ABG), with ABG projecting 40-50% volume growth next year, and Mold-Tek being ready with machinery and molds for this.
- →The company is optimistic about increasing volumes from pharma, food, FMCG, and thin packs due to new product launches like Surf Excel and Horlicks.
- →Asian Paints volumes have declined recently, but the company expects stabilization or recovery, especially with increased adoption of In-Mold Labeling (IML) products.
- →Pharma segment is scaling up, with commercial supplies increasing and capacity utilization nearing 40-45%.
- →The newly added printing capacity (40% increase) will help meet demand and reduce supply disruptions.
- →Overall, expected growth is in double digits for the next financial year driven by ABG and pharma growth.
Capex plans
Yes- →Pharma segment capex planned for FY '25-'26 is INR 25-40 crores, mainly for additional machines and molds to double capacity; land and building are already in place.
- →Potential expansion in Sultanpur premises may require an additional INR 8-10 crores for new buildings.
- →Other plants (Cheyyar, Panipat, Mahad) will see mostly balancing equipment investments, with Mahad possibly requiring INR 10-15 crores.
- →Total capex for next financial year expected to reduce to around INR 60-65 crores from INR 120-130 crores over the last 3 years.
- →No significant greenfield projects planned; focus is on pharma capacity build-up and incremental investments in existing plants to support growth.
- →Paint industry capex readiness is in place with new machinery and molds arriving, especially for anticipated volume growth from Aditya Birla Group.
How does Mold-Tek Packaging Ltd rank vs peers in Industrial Products?
Pro feature1Mold-Tek Packaging Ltd
Rev 3Mar 1
See full Industrial Products sector rankings
Want more stocks like Mold-Tek Packaging Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio